Comparison of the effect of oral captopril with sublingual captopril in lowering blood pressure in patients with acute high blood pressure

Comparison of the effect of oral captopril with sublingual captopril on blood pressure of patients referred to hospital emergency room

A clinical trial with a control group with a three-way blind phase three parallel group on 138 patients, rand function of Excel software will be used for randomization.

Randomization is done through variable blocking, and for the purpose of three-way blinding and without informing the randomizer, the drug and placebo are placed in an envelope with a code, and after measuring the blood pressure of the primary subjects, the drug and placebo are prescribed to the patient. In the group prescribed oral captopril 25 mg of Elixir Pharmaceutical Company, in order to blind the patient, simultaneous sublingual placebo was prescribed, and in the group prescribed sublingual captopril 25 mg of Elixir Pharmaceutical Company and placebo were administered orally at the same time.

Inclusion criteria: patients with systolic blood pressure above 160 or diastolic blood pressure above 100 referring to the FAST (outpatient) emergency department of Khatam al-Anbia Hospital in 1401 Exclusion criteria: 1) Patients who need blood pressure injection treatment and hospitalization. 2) Patients who have used blood pressure pills an hour before the visit. 3) Patients who have a history of kidney problems. 4) Patients who are over 65 years old. 5 ) Patients who are younger than 18 years old 6) Patients with end organ damage 7) Pregnancy 8) Decreased level of consciousness

After randomization, patients are divided into two groups and receive either oral captopril or sublingual captopril.

Blood pressure ؛ blood pressure assessment time

Random allocation of patients to two groups is done by permuted block stratified randomization method designed with Random allocation software. In this way, first, eligible referring patients are classified according to age and gender in the order of entry. Then they are assigned to the desired group based on blocks of 4 (consisting of two groups A and B and two repetitions for each) randomly selected from among all the possible states of permutations. In order to hide the random allocation, envelopes will be used in the package.

In this research, the triple-blind method is used. The patients will receive both forms of administration (sublingual and oral) with drugs and placebo and will be blinded to being in the intervention or control group. The data collector measures the desired outcomes and does not know which group the patient is in. The data analyst compares two groups coded A and B and is blinded to the control and intervention groups. .

All data is potentially shareable after de-identifying individuals

The access period starts 12 months after the results are published

Seas of documents will be available for researchers working in academic and scientific institutions

For medical purposes, pharmaceutical companies can receive data analysis after sending a request.

Applicants should write to the following postal address. ali.abdorazzagh@gamil.com

After sending the request to the said postal address, as well as stating the purpose of accessing the data and documents, the applicant will receive the documents within a period of 12 weeks, if there is no conflict with the codes of medical ethics.